• Dentsply Sirona recently expanded its U.S. distribution footprint by broadening its partnership with Nashville Dental Inc., enabling dental practices across a nine-state region to access its full suite of connected technologies, including CEREC systems, Primescan scanners, and digital imaging solutions through a locally focused distributor.
• This move highlights how Dentsply Sirona is leaning on an indirect, service-heavy channel to encourage wider adoption of digitally integrated dentistry workflows in key regional markets.
• We’ll now examine how this broader Nashville Dental partnership, centered on connected digital workflows, may influence Dentsply Sirona’s existing investment narrative.

Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

DENTSPLY SIRONA Investment Narrative Recap

To own Dentsply Sirona, you need to believe its shift toward digitally connected dentistry and platforms like CEREC and DS Core can eventually offset recent revenue pressure, net losses, and execution hiccups. The expanded Nashville Dental partnership modestly supports the near term catalyst of better utilization of existing digital assets, but it does not remove the central risk that ongoing U.S. weakness, cost headwinds, and soft demand in elective categories could continue to weigh on growth and margins.

The most relevant recent announcement alongside the Nashville Dental deal is Dentsply Sirona’s broader U.S. distribution refresh in early 2026, including expanded agreements with Patterson, Benco, Atlanta Dental, and Burkhart. Together, these moves deepen the indirect, service heavy channel for CEREC, Primescan, and imaging, which could be important if the company is to translate its sizeable installed base and AI driven launches into higher utilization and better support for its “return to growth” ambitions.

Yet beneath this push into connected workflows, there is a less visible risk investors should be aware of around persistent softness in high margin elective categories and...

DENTSPLY SIRONA's narrative projects $3.7 billion revenue and $161.6 million earnings by 2029.

Uncover how DENTSPLY SIRONA's forecasts yield a $14.54 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Some higher end analysts were assuming revenues of about US$3.9 billion and earnings near US$240 million by 2029, which is far more optimistic than the consensus that still flags slower DS Core monetization as a key risk, and this new Nashville Dental expansion could eventually shift how you judge which of those stories feels closer to reality.

Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth just $14.54!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.